225 related articles for article (PubMed ID: 8631538)
1. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
2. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Facchini V; Genazzani AR
Anticancer Res; 1995; 15(6B):2683-6. PubMed ID: 8669847
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
Gadducci A; Baicchi U; Marrai R; Del Bravo B; Fosella PV; Facchini V
Gynecol Oncol; 1994 Jun; 53(3):352-6. PubMed ID: 8206409
[TBL] [Abstract][Full Text] [Related]
4. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
7. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer.
Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Weiss C; Genazzani AR
Gynecol Oncol; 1997 Jul; 66(1):85-8. PubMed ID: 9234926
[TBL] [Abstract][Full Text] [Related]
8. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
9. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
10. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
11. Can we preoperatively risk stratify ovarian masses for malignancy?
Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
[TBL] [Abstract][Full Text] [Related]
12. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
16. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
Worasethsin P; Narkwichean A
J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
20. A multivariate logistic regression analysis in predicting malignancy for patients with ovarian tumors.
Hata K; Akiba S; Hata T; Miyazaki K
Gynecol Oncol; 1998 Mar; 68(3):256-62. PubMed ID: 9570977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
